Condition: Locally Advanced Solid Tumor · Metastatic Solid Tumor · Sponsor: Ipsen
This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original location. All participants will receive the drug by injection. Study Phases: * Phase Ia: Participants with certain types of tumours will be treated in cohorts of increasingly higher doses of the drug to determine the safe and effective dose range (a high and a low dose). * Phase Ib: Participants with a specific tumour type will receive one of the two doses identified in phase Ia. The dose level will be assigned randomly (by chance). Study Periods: Screening: Up to 28 days before first IPN60300 injection to determine eligibility. Treatment: Starts with the first dose of IPN60300 and continues until it needs to be stopped due to harmful effects, the disease getting worse, or if the participant decides to stop taking part in the study, the investigator's decision to stop treatment, death or the study is terminated early by the sponsor. Participants will undergo blood tests, urine collections, physical examinations, and clinical evaluations.
This description comes directly from the study's public registry record.
Ipsen Clinical Study Enquiries · See e mail · clinical.trials@ipsen.com
Always discuss trial participation with your own doctor first.
| Yale Cancer Center-Yale University | New Haven, Connecticut, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Sidney Kimmel Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| NEXT Oncology | Fairfax, Virginia, United States | Recruiting |
| Centre Leon Berard | Lyon, France | Recruiting |
| Institut de Cancerologie de l'Ouest (ICO)- CRLCC Rene Gauducheau | Saint-Herblain, France | Recruiting |
| Gustave Roussy Cancer Campus Grand Paris- (Institut de Cancerologie Gustave-Roussy) | Villejuif, France | Recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona, Spain | Not Yet Recruiting |
| NEXT Quiron-Barcelona | Barcelona, Spain | Not Yet Recruiting |
| START Madrid CIOCC Hospital Universitario HM Sanchinarro | Madrid, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07213817